- Conditions
- Percentage of Change in ONSD During Anesthesia With Sevoflurane Versus Propofol in Two Groups of Patients
- Interventions
- Sevoflurane Inhalant Product, Propofol 10 MG/ML
- Drug
- Lead sponsor
- State University of New York - Downstate Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 729
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- alpha-lipoic acid and L-acetyl carnitine
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cancer
- Interventions
- isolated perfusion, melphalan
- Drug
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Interventions
- cilengitide, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Choroidal Melanoma, Indeterminate Lesions of Eye
- Interventions
- Not listed
- Lead sponsor
- Aura Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Los Angeles, California • Palo Alto, California + 13 more
- Conditions
- Primary Open Angle Glaucoma, Low Tension Glaucoma, Cataract, Ocular Hypertension
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Leber's Hereditary Optic Neuropathy (LHON)
- Interventions
- Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))
- Device
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 3
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, Ocular Melanoma, Uveal Melanoma, Iris Melanoma, Conjunctival Melanoma, Non-Cutaneous Melanoma
- Interventions
- TBio-4101, Cyclophosphamide, Fludarabine, Interleukin-2
- Biological · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Melanoma
- Interventions
- Revlimid
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Opsoclonus-myoclonus Syndrome, Opsoclonus, Myoclonus, Ataxia
- Interventions
- rituximab
- Drug
- Lead sponsor
- National Pediatric Neuroinflammation Organization, Inc.
- Other
- Eligibility
- 6 Months to 19 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Springfield, Illinois
- Conditions
- Diabetic Retinopathy
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska
- Conditions
- Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
- Interventions
- Everolimus (RAD001), Everolimus Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
- Conditions
- Retinoblastoma, Eye Cancer
- Interventions
- Intra-arterial infusion of chemotherapy
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Cancer
- Interventions
- cyclophosphamide, Cryoablation
- Drug · Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Supranuclear Palsy, Progressive
- Interventions
- BIIB092, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 41 Years to 86 Years
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 25 more
- Conditions
- Neuromyelitis Optica, Myelitis, Transverse, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System
- Interventions
- Mitoxantrone
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Non Arteritic Anterior Ischemic Optic Neuropathy
- Interventions
- QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg, Sham Injection Procedure
- Drug · Other
- Lead sponsor
- Quark Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 44
- States / cities
- Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 35 more
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
- Interventions
- Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide, Ipilimumab
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Convergence Insufficiency
- Interventions
- Pencil Push-ups, Office-based Vision Therapy, Placebo Office-based Vision Therapy
- Procedure
- Lead sponsor
- Pennsylvania College of Optometry
- Industry
- Eligibility
- 9 Years to 30 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2001
- U.S. locations
- 7
- States / cities
- Fullerton, California • New York, New York • Columbus, Ohio + 3 more
- Conditions
- Glaucoma, Open Angle
- Interventions
- brimonidine, timolol
- Drug
- Lead sponsor
- Chicago Center for Vision Research
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Gainesville, Florida • Palm Beach Gardens, Florida + 7 more
- Conditions
- Melanoma (Skin), Intraocular Melanoma
- Interventions
- Xenogeneic Tyrosinase DNA Vaccine, TriGrid Delivery System for Intramuscular Electroporation
- Biological · Device
- Lead sponsor
- Ichor Medical Systems Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ischemic Optic Neuropathy
- Interventions
- Surgery
- Procedure
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1994
- U.S. locations
- 24
- States / cities
- Los Angeles, California • San Francisco, California • Gainesville, Florida + 20 more
- Conditions
- Supranuclear Palsy, Progressive
- Interventions
- BIIB092
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 41 Years to 86 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
- Conditions
- Ocular Melanoma
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 20 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia